Related Experiment Videos
Does maximal androgen blockade (MAB) improve survival? A critical appraisal of the evidence
Laurence H. Klotz1, Toni Newman
1Department of Surgery, University of Toronto, Sunnybrook Health Science Center, Toronto, Ontario.
The Canadian Journal of Urology
|September 1, 1996
Abstract:
The conflicting data surrounding the benefit of total androgen blockade compared to monotherapy for metastatic prostate cancer is reviewed. The recent Lancet meta-analysis is critically appraised. A sensitivity analysis of the studies is presented.